Back to Search
Start Over
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
- Source :
- Biblos-e Archivo. Repositorio Institucional de la UAM, instname, Blood Cancer Journal, Vol 11, Iss 10, Pp 1-4 (2021), Blood Cancer Journal
- Publication Year :
- 2021
- Publisher :
- Nature Publishing, 2021.
-
Abstract
- The ICARIA-MM study was sponsored by Sanofi. The authors thank, Helgi van de Velde, Valérie Boutet, Shujia Dai, Deborah DiNoto, Graziella Engelvin, Olivier Fedeli, Sébastien Hugla, Dominique Mouret, Béatrice Pradeilles, and Alain Roccon, all employees of Sanofi, for their contribution to the study, technology, and comments on the manuscript. The authors thank the participating patients and their families, and the study centers and investigators, for their contributions to the study. The medical writing support was provided by John Clarke, PhD and Stephanie Brillhart, PhD of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services.
- Subjects :
- medicine.medical_specialty
Medicina
medicine.medical_treatment
Antibodies, Monoclonal, Humanized
Dexamethasone
Internal medicine
Correspondence
Antineoplastic Combined Chemotherapy Protocols
medicine
Multiple myeloma
RC254-282
Isatuximab
Hematology
biology
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immunotherapy
Middle Aged
medicine.disease
Pomalidomide
Minimal residual disease
Thalidomide
Oncology
biology.protein
Cancer research
Randomized controlled trials
Tumour immunology
Antibody
business
Multiple Myeloma
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Biblos-e Archivo. Repositorio Institucional de la UAM, instname, Blood Cancer Journal, Vol 11, Iss 10, Pp 1-4 (2021), Blood Cancer Journal
- Accession number :
- edsair.doi.dedup.....42388660db58cc474f6a703d05ad600e